The interactions of anti-cancer drugs approved in the last decade in the United States with membrane transporters

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 8, 2010, Pages 601-616

  Jain, Lokesh ^a   Abraham, Sophia ^a   Shord, Stacy S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cytotoxic agents; Drug resistance; Drug drug interactions; Hormonal therapies; Pharmacokinetics; Targeted anticancer therapies; Transporters

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CLOFARABINE; DASATINIB; DEGARELIX; ERLOTINIB; EVEROLIMUS; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; IXABEPILONE; LAPATINIB; LETROZOLE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NELARABINE; NILOTINIB; PAZOPANIB; PEMETREXED; PRALATREXATE; RALOXIFENE; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BREAST CANCER; CANCER HORMONE THERAPY; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSPORT; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MEMBRANE TRANSPORT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPOROSIS; PANCREAS CANCER; PROSTATE CANCER; REVIEW; T CELL LYMPHOMA; TUMOR RESISTANCE; UNITED STATES;

EID: 79551616913     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794473966     Document Type: Review

References (158)

1. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today, 2008, 13 (9-10), 379-393.
2. Huang Y, Sadée W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett., 2006, 239(2), 168-182.
3. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9(3), 215-236.
4. Sissung, T.M.; Baum, C.E.; Deeken, J; Price, D.K.; Aragon-Ching, J.; Steinberg, S.M.; Dahut, W.; Sparreboom, A.; Figg, W.D.; ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin. Cancer Res., 2008, 14(14), 4543-4549.
5. Glimelius, B.; Garmo, H.; Berglund. A.; Fredriksson, L.A.; Berglund, M.; Kohnke, H.; Byström, P.; Sørbye, H.; Wadelius, M. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J., 2010, Feb 23. [Epub ahead of print]
6. Hediger, M.A.; Romero, M.F.; Peng, J.B.; Rolfs, A.; Takanaga, H.; Bruford, E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Eur. J. Physiol., 2004, 447(5), 465-468.
7. Kim, R.B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest., 2003, 33 (Suppl 2), 1-5.
8. Koepsell, H.; Endou, H. The SLC22 drug transporter family. Eur. J. Physiol., 2004, 447(5), 666-676.
9. Benet, L. Z.; Cummins, C. L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev., 2001, 50 (Suppl 1), S3-11.
10. Velcade (bortezomib) prescribing information. Millennium Pharmaceuticals, Inc. http://www.velcade.com/Files/PDFs/ VELCADE_PRESCRIBING_INFORMATION.pdf. (Accessed Dec 10, 2010)
11. Ooi, M.G.; O'Connor, R.; Jakubikova, J.; Meiller, J.; Klippel, S.; Delmore, J.; Kastritis, E.; McMillin, D.; Clynes, M.; Richardson, P.; Mitsiades, C. S.; O'Gorman, P.; Anderson, K. C. Interaction of bortezomib with P-gp, MRP-1 and BCRP drug transporters: Implications for therapeutic applications of Bortezomib in advanced multiple myeloma and other neoplasias. 51th ASH Annual meeting and Exposition, December 5, 2009.
12. Panischeva, L.A.; Kakpakova, E.S.; Rybalkina, E.Y.; Stavrovskaya, A.A. The influence of proteasome inhibitor Bortezamib on ABC transporters' expression and activity in tumor cells. Membr. Cell Biol., 2010, 4, 220-225.
13. Sprycel (dasatinib) prescribing information. Bristol-Myers Squibb Company http://packageinserts.bms.com/pi/pi_sprycel.pdf (Accessed Oct 18, 2010)
14. Kamath, A. V.; Wang, J.; Lee, F. Y.; Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol., 2008, 61 (3), 365-376.
15. Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist, W. F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther., 2009, 330 (3), 956-963.
16. Davies, A.; Jordanides, N. E.; Giannoudis, A.; Lucas, C. M.; Hatziieremia, S.; Harris, R. J.; Jorgensen, H. G.; Holyoake, T. L.; Pirmohamed, M.; Clark, R. E.; Mountford, J. C. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 2009, 23 (11), 1999-2006.
17. Giannoudis, A.; Davies, A.; Lucas, C. M.; Harris, R. J.; Pirmohamed, M.; Clark, R. E. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood, 2008, 112 (8), 3348-3354.
18. Hegedus, C.; Ozvegy-Laczka, C.; Apati, A.; Magocsi, M.; Nemet, K.; Orfi, L.; Keri, G.; Katona, M.; Takats, Z.; Varadi, A.; Szakacs, G.; Sarkadi, B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol., 2009, 158 (4), 1153-1164.
19. Hiwase, D. K.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L. B.; Melo, J.; Kumar, S.; Hughes, T. P.; White, D. L. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res., 2008, 14 (12), 3881-3888.
20. Lagas, J. S.; van Waterschoot, R. A.; van Tilburg, V. A.; Hillebrand, M. J.; Lankheet, N.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Brain accumulation of dasatinib is restricted by Pglycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res., 2009, 15 (7), 2344-2351.
21. Tarceva (erlotinib) prescribing information. Genentech USA, Inc. http://www.gene.com/gene/products/information/pdf/tarcevaprescribing.pdf (Accessed Oct 18, 2010).
22. Marchetti, S.; de Vries, N. A.; Buckle, T.; Bolijn, M. J.; van Eijndhoven, M. A.; Beijnen, J. H.; Mazzanti, R.; van, T. O.; Schellens, J. H. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/-(tripleknockout) and wild-type mice. Mol. Cancer Ther., 2008, 7 (8), 2280-2287.
23. Rudin, C. M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D. L.; Chen, P.; Armstrong, D. K.; Brahmer, J. R.; Fleming, G. F.; Vokes, E. E.; Carducci, M. A.; Ratain, M. J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol., 2008, 26 (7), 1119-1127.
24. Noguchi, K.; Kawahara, H.; Kaji, A.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Substrate-dependent bidirectional modulation of Pglycoprotein-mediated drug resistance by erlotinib. Cancer Sci., 2009, 100 (9), 1701-1707.
25. Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A.; Robey, R. W.; Bates, S. E.; Hidalgo, M.; Baker, S. D. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther., 2007, 6 (3), 432-438.
26. Kuang, Y. H.; Shen, T.; Chen, X.; Sodani, K.; Hopper-Borge, E.; Tiwari, A. K.; Lee, J. W.; Fu, L. W.; Chen, Z. S. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol., 2010, 79 (2), 154-161.
27. Afinitor (everolimus) prescribing information 2009. Novartis Pharmaceuticals Corporation. http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf (Accessed Oct 18, 2010)
28. Crowe, A.; Bruelisauer, A.; Duerr, L.; Guntz, P.; Lemaire, M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab. Dispos. 1999, 27 (5), 627-632.
29. Chu, C.; Abbara, C.; Noel-Hudson, M. S.; Thomas-Bourgneuf, L.; Gonin, P.; Farinotti, R.; Bonhomme-Faivre, L. Disposition of everolimus in mdr1a-/1b-mice and after a pre-treatment of lapatinib in Swiss mice. Biochem. Pharmacol., 2009, 77 (10), 1629-1634.
30. Laplante, A.; Demeule, M.; Murphy, G. F.; Beliveau, R. Interaction of immunosuppressive agents rapamycin and its analogue SDZRAD with endothelial P-gp. Transplant. Proc., 2002, 34 (8), 3393-3395.
31. Kovarik, J. M.; Beyer, D.; Bizot, M. N.; Jiang, Q.; Allison, M. J.; Schmouder, R. L. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br. J. Clin. Pharmacol., 2005, 60 (4), 434-437.
32. Brandhorst, G.; Tenderich, G.; Zittermann, A.; Oezpeker, C.; Koerfer, R.; Oellerich, M.; Armstrong, V. W. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther. Drug Monit., 2008, 30 (1), 113-116.
33. Iressa (gefitinib) prescribing information. 2004. AstraZeneca Pharmaceuticals LP. http://www.1.astrazeneca-us.com/pi/iressa.pdf (Accessed Oct 18, 2010)
34. Nakamura, Y.; Oka, M.; Soda, H.; Shiozawa, K.; Yoshikawa, M.; Itoh, A.; Ikegami, Y.; Tsurutani, J.; Nakatomi, K.; Kitazaki, T.; Doi, S.; Yoshida, H.; Kohno, S. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res., 2005, 65 (4), 1541-1546.
35. Yanase, K.; Tsukahara, S.; Asada, S.; Ishikawa, E.; Imai, Y.; Sugimoto, Y. Gefitinib reverses breast cancer resistance proteinmediated drug resistance. Mol. Cancer Ther., 2004, 3 (9), 1119-1125.
36. Akasaka, K.; Kaburagi, T.; Yasuda, S.; Ohmori, K.; Abe, K.; Sagara, H.; Ueda, Y.; Nagao, K.; Imura, J.; Imai, Y. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother. Pharmacol., 2010, 66 (4), 691-698.
37. Shi, Z.; Peng, X. X.; Kim, I. W.; Shukla, S.; Si, Q. S.; Robey, R. W.; Bates, S. E.; Shen, T.; Ashby, C. R., Jr.; Fu, L. W.; Ambudkar, S. V.; Chen, Z. S. Erlotinib (Tarceva, OSI-774) antagonizes ATPbinding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res., 2007, 67 (22), 11012-11020.
38. Carcaboso, A. M.; Elmeliegy, M. A.; Shen, J.; Juel, S. J.; Zhang, Z. M.; Calabrese, C.; Tracey, L.; Waters, C. M.; Stewart, C. F. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res., 2010, 70 (11), 4499-4508.
39. Leggas, M.; Panetta, J. C.; Zhuang, Y.; Schuetz, J. D.; Johnston, B.; Bai, F.; Sorrentino, B.; Zhou, S.; Houghton, P. J.; Stewart, C. F. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res., 2006, 66 (9), 4802-4807.
40. Nagashima, S.; Soda, H.; Oka, M.; Kitazaki, T.; Shiozawa, K.; Nakamura, Y.; Takemura, M.; Yabuuchi, H.; Fukuda, M.; Tsukamoto, K.; Kohno, S. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother. Pharmacol., 2006, 58 (5), 594-600.
41. Yang, C. H.; Huang, C. J.; Yang, C. S.; Chu, Y. C.; Cheng, A. L.; Whang-Peng, J.; Yang, P. C. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res., 2005, 65 (15), 6943-6949.
42. Furman, W. L.; Navid, F.; Daw, N. C.; McCarville, M. B.; McGregor, L. M.; Spunt, S. L.; Rodriguez-Galindo, C.; Panetta, J. C.; Crews, K. R.; Wu, J.; Gajjar, A. J.; Houghton, P. J.; Santana, V. M.; Stewart, C. F. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J. Clin. Oncol., 2009, 27 (27), 4599-4604.
43. Stewart, C. F.; Leggas, M.; Schuetz, J. D.; Panetta, J. C.; Cheshire, P. J.; Peterson, J.; Daw, N.; Jenkins, J. J., III; Gilbertson, R.; Germain, G. S.; Harwood, F. C.; Houghton, P. J. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res., 2004, 64 (20), 7491-7499.
44. Cusatis, G.; Gregorc, V.; Li, J.; Spreafico, A.; Ingersoll, R. G.; Verweij, J.; Ludovini, V.; Villa, E.; Hidalgo, M.; Sparreboom, A.; Baker, S. D. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst., 2006, 98 (23), 1739-1742.
45. Agarwal, S.; Sane, R.; Gallardo, J. L.; Ohlfest, J. R.; Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther., 2010, 334 (1), 147-155.
46. Galetti, M.; Alfieri, R. R.; Cavazzoni, A.; La, M. S.; Bonelli, M.; Fumarola, C.; Mozzoni, P.; De, P. G.; Andreoli, R.; Mutti, A.; Mor, M.; Tiseo, M.; Ardizzoni, A.; Petronini, P. G. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochem. Pharmacol., 2010, 80 (2), 179-187.
47. Gleevec (Imatinib mesylate) prescribing information. Novartis Pharmaceuticals Corporation http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf (Accessed Oct 18, 2010)
48. Assef, Y.; Rubio, F.; Colo, G.; del, M. S.; Costas, M. A.; Kotsias, B. A. Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk. Res., 2009, 33 (5), 710-716.
49. Burger, H.; van, T. H.; Boersma, A. W.; Brok, M.; Wiemer, E. A.; Stoter, G.; Nooter, K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104 (9), 2940-2942.
50. Czyzewski, K.; Styczynski, J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma, 2009, 56 (3), 202-207.
51. Graber-Maier, A.; Gutmann, H.; Drewe, J. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as Imatinib. Mol. Pharm., 2010. [EPub ahead of Print]
52. Hatziieremia, S.; Jordanides, N. E.; Holyoake, T. L.; Mountford, J. C.; Jorgensen, H. G. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp. Hematol., 2009, 37 (6), 692-700.
53. Houghton, P. J.; Germain, G. S.; Harwood, F. C.; Schuetz, J. D.; Stewart, C. F.; Buchdunger, E.; Traxler, P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res., 2004, 64 (7), 2333-2337.
54. Hu, S.; Franke, R. M.; Filipski, K. K.; Hu, C.; Orwick, S. J.; de Bruijn, E. A.; Burger, H.; Baker, S. D.; Sparreboom, A. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res., 2008, 14 (10), 3141-3148
55. Muenster, U.; Grieshop, B.; Ickenroth, K.; Gnoth, M. J. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm. Res., 2008, 25 (10), 2320-2326.
56. Widmer, N.; Rumpold, H.; Untergasser, G.; Fayet, A.; Buclin, T.; Decosterd, L. A. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia, 2007, 21 (7), 1561-1562.
57. Jordanides, N.E.; Jorgensen, H.G.; Holyoake, T.L.; Mountford, J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 2006, 18 (4), 1370-1373.
58. Gurney, H.; Wong, M.; Balleine, R. L.; Rivory, L. P.; McLachlan, A. J.; Hoskins, J. M.; Wilcken, N.; Clarke, C. L.; Mann, G. J.; Collins, M.; Delforce, S. E.; Lynch, K.; Schran, H. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther., 2007, 82 (1), 33-40.
59. Cortes, J. E.; Egorin, M. J.; Guilhot, F.; Molimard, M.; Mahon, F. X. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23 (9), 1537-1544.
60. Widmer, N.; Decosterd, L. A.; Leyvraz, S.; Duchosal, M. A.; Rosselet, A.; Debiec-Rychter, M.; Csajka, C.; Biollaz, J.; Buclin, T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br. J. Cancer 2008, 98 (10), 1633-1640.
61. Petain, A.; Kattygnarath, D.; Azard, J.; Chatelut, E.; Delbaldo, C.; Geoerger, B.; Barrois, M.; Seronie-Vivien, S.; LeCesne, A.; Vassal, G. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res., 2008, 14 (21), 7102-7109.
62. Dulucq, S.; Bouchet, S.; Turcq, B.; Lippert, E.; Etienne, G.; Reiffers, J.; Molimard, M.; Krajinovic, M.; Mahon, F. X. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2008, 112 (5), 2024-2027.
63. Ni, L. N.; Li, J. Y.; Miao, K. R.; Qiao, C.; Zhang, S. J.; Qiu, H. R.; Qian, S. X. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol., 2010. [Epub Ahead of Print]
64. Gardner, E. R.; Burger, H.; van Schaik, R. H.; van Oosterom, A. T.; de Bruijn, E. A.; Guetens, G.; Prenen, H.; de Jong, F. A.; Baker, S. D.; Bates, S. E.; Figg, W. D.; Verweij, J.; Sparreboom, A.; Nooter, K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther., 2006, 80 (2), 192-201.
65. Crossman, L. C.; Druker, B. J.; Deininger, M. W.; Pirmohamed, M.; Wang, L.; Clark, R. E. hOCT 1 and resistance to imatinib. Blood, 2005, 106 (3), 1133-1134.
66. Wang, L.; Giannoudis, A.; Lane, S.; Williamson, P.; Pirmohamed, M.; Clark, R. E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther., 2008, 83 (2), 258-264.
67. Shen, T.; Kuang, Y. H.; Ashby, C. R.; Lei, Y.; Chen, A.; Zhou, Y.; Chen, X.; Tiwari, A. K.; Hopper-Borge, E.; Ouyang, J.; Chen, Z. S. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One, 2009, 4 (10), e7520.
68. Hirayama, C.; Watanabe, H.; Nakashima, R.; Nanbu, T.; Hamada, A.; Kuniyasu, A.; Nakayama, H.; Kawaguchi, T.; Saito, H. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm. Res., 2008, 25 (4), 827-835.
69. Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 2004, 104 (12), 3739-3745.
70. White, D. L.; Saunders, V. A.; Dang, P.; Engler, J.; Zannettino, A. C.; Cambareri, A. C.; Quinn, S. R.; Manley, P. W.; Hughes, T. P. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 2006, 108 (2), 697-704.
71. Tykerb (lapatinib) prescribing information. GlaxoSmithKline. http://us.gsk.com/products/assets/us_tykerb.pdf (Accessed Oct 18, 2010)
72. Polli, J. W.; Humphreys, J. E.; Harmon, K. A.; Castellino, S.; O'Mara, M. J.; Olson, K. L.; John-Williams, L. S.; Koch, K. M.; Serabjit-Singh, C. J. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. 2008, 36 (4), 695-701.
73. Polli, J. W.; Olson, K. L.; Chism, J. P.; John-Williams, L. S.; Yeager, R. L.; Woodard, S. M.; Otto, V.; Castellino, S.; Demby, V. E. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos., 2009, 37 (2), 439-442.
74. Dai, C. L.; Tiwari, A. K.; Wu, C. P.; Su, X. D.; Wang, S. R.; Liu, D. G.; Ashby, C. R., Jr.; Huang, Y.; Robey, R. W.; Liang, Y. J.; Chen, L. M.; Shi, C. J.; Ambudkar, S. V.; Chen, Z. S.; Fu, L. W. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res., 2008, 68 (19), 7905-7914.
75. Molina, J. R.; Kaufmann, S. H.; Reid, J. M.; Rubin, S. D.; Galvez-Peralta, M.; Friedman, R.; Flatten, K. S.; Koch, K. M.; Gilmer, T. M.; Mullin, R. J.; Jewell, R. C.; Felten, S. J.; Mandrekar, S.; Adjei, A. A.; Erlichman, C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin. Cancer Res., 2008, 14 (23), 7900-7908.
76. Vannini, I.; Zoli, W.; Fabbri, F.; Ulivi, P.; Tesei, A.; Carloni, S.; Brigliadori, G.; Amadori, D. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anticancer Drugs, 2009, 20 (10), 918-925.
77. Midgley, R. S.; Kerr, D. J.; Flaherty, K. T.; Stevenson, J. P.; Pratap, S. E.; Koch, K. M.; Smith, D. A.; Versola, M.; Fleming, R. A.; Ward, C.; O'Dwyer, P. J.; Middleton, M. R. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann. Oncol., 2007, 18 (12), 2025-2029.
78. Tasigna (nilotinib) prescribing information. Novartis Pharmaceuticals Corporation. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022068s002lbl.pdf (Accessed Oct 18, 2010)
79. Mahon, F. X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res., 2008, 68 (23), 9809-9816.
80. Tiwari, A. K.; Sodani, K.; Wang, S. R.; Kuang, Y. H.; Ashby, C. R., Jr.; Chen, X.; Chen, Z. S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol., 2009, 78 (2), 153-161.
81. Haouala, A.; Rumpold, H.; Untergasser, G.; Buclin, T.; Ris, H. B.; Widmer, N.; Decosterd, L. A. siRNA-Mediated Knock-Down of PGlycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. Drug Metab. Lett., 2010, 4 (2), 114-119.
82. Engler, J. R.; Frede, A.; Saunders, V. A.; Zannettino, A. C.; Hughes, T. P.; White, D. L. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010, 24 (4), 765-770.
83. Dohse, M.; Scharenberg, C.; Shukla, S.; Robey, R. W.; Volkmann, T.; Deeken, J. F.; Brendel, C.; Ambudkar, S. V.; Neubauer, A.; Bates, S. E. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos., 2010, 38 (8), 1371-1380.
84. Votrient (pazopanib) prescribing information. GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465 lbl.pdf (Accessed Oct 18, 2010)
85. Xu, C. F.; Reck, B. H.; Xue, Z.; Huang, L.; Baker, K. L.; Chen, M.; Chen, E. P.; Ellens, H. E.; Mooser, V. E.; Cardon, L. R.; Spraggs, C. F.; Pandite, L. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br. J. Cancer, 2010, 102 (9), 1371-1377.
86. Istodax (romidepsin) prescribing information. Gloucester Pharmaceuticals, Inc. http://www.accessdata.fda.gov/drugsatfda_ docs/label/2009/022393lbl.pdf (Accessed Oct 18, 2010)
87. Robey, R. W.; Zhan, Z.; Piekarz, R. L.; Kayastha, G. L.; Fojo, T.; Bates, S. E. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res., 2006, 12 (5), 1547-1555.
88. Piekarz, R. L.; Robey, R. W.; Zhan, Z.; Kayastha, G.; Sayah, A.; Abdeldaim, A. H.; Torrico, S.; Bates, S. E. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 2004, 103 (12), 4636-4643.
89. Xiao, J. J.; Foraker, A. B.; Swaan, P. W.; Liu, S.; Huang, Y.; Dai, Z.; Chen, J.; Sadee, W.; Byrd, J.; Marcucci, G.; Chan, K. K. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol. Exp. Ther., 2005, 313 (1), 268-276.
90. Xiao, J. J.; Huang, Y.; Dai, Z.; Sadee, W.; Chen, J.; Liu, S.; Marcucci, G.; Byrd, J.; Covey, J. M.; Wright, J.; Grever, M.; Chan, K. K. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol. Exp Ther., 2005, 314 (1), 467-475.
91. Yamada, H.; Arakawa, Y.; Saito, S.; Agawa, M.; Kano, Y.; Horiguchi-Yamada, J. Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. Leuk. Res., 2006, 30 (6), 723-734.
92. Tabe, Y.; Konopleva, M.; Contractor, R.; Munsell, M.; Schober, W. D.; Jin, L.; Tsutsumi-Ishii, Y.; Nagaoka, I.; Igari, J.; Andreeff, M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood, 2006, 107 (4), 1546-1554.
93. Gandhi, Y. A.; Morris, M. E. Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J., 2009, 11 (3), 541-552.
94. Woo, S.; Gardner, E. R.; Chen, X.; Ockers, S. B.; Baum, C. E.; Sissung, T. M.; Price, D. K.; Frye, R.; Piekarz, R. L.; Bates, S. E.; Figg, W. D. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin. Cancer Res., 2009, 15 (4), 1496-1503.
95. Bates, S. E.; Zhan, Z.; Steadman, K.; Obrzut, T.; Luchenko, V.; Frye, R.; Robey, R. W.; Turner, M.; Gardner, E. R.; Figg, W. D.; Steinberg, S. M.; Ling, A.; Fojo, T.; To, K. W.; Piekarz, R. L. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br. J. Haematol., 2010, 148 (2), 256-267.
96. Nexavar (Sorafenib) Prescribing Information. Bayer Pharmaceuticals, Inc. http://www.nexavar.com/html/download/ Nexavar_PI.pdf (Accessed Oct 18, 2010).
97. Wei, L.; Su, N.; Zheng, D. Y.; Cao, M. R.; Li, A. M.; Yan, X.; Lu, C. W.; Luo, R. C. Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib. Xi. Bao. Yu. Fen. Zi Mian. Yi. Xue. Za. Zhi. 2009, 25 (4), 344-347.
98. Wei, L.; Huang, N.; Yang, L.; Zheng, D. Y.; Cui, Y. Z.; Li, A. M.; Lu, C. W.; Zheng, H.; Luo, R. C. Sorafenib reverses multidrug resistance of hepatoma cells in vitro. Nan. Fang. Yi Ke. Da. Xue Xue Bao, 2009, 29 (5), 1016-9, 1023.
99. Hu, S.; Chen, Z.; Franke, R.; Orwick, S.; Zhao, M.; Rudek, M. A.; Sparreboom, A.; Baker, S. D. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATPbinding cassette transporters. Clin. Cancer Res., 2009, 15 (19), 6062-6069.
100. Gnoth, M. J.; Sandmann, S.; Engel, K.; Radtke, M. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-Glycoprotein. Drug Metab. Dispos., 2010, 38 (8), 1341-1346.
101. Sutent (Sunitinib) prescribing information. Pfizer, Inc. http://www.pfizer.com/files/products/uspi_sutent.pdf (Accessed Oct 18, 2010)
102. Shukla, S.; Robey, R. W.; Bates, S. E.; Ambudkar, S. V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos., 2009, 37 (2), 359-365.
103. Dai, C. L.; Liang, Y. J.; Wang, Y. S.; Tiwari, A. K.; Yan, Y. Y.; Wang, F.; Chen, Z. S.; Tong, X. Z.; Fu, L. W. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett., 2009, 279 (1), 74-83.
104. Kawahara, H.; Noguchi, K.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene. Cancer Sci. 2010. [Epub Ahead of Print]
105. Bello, C. L.; Sherman, L.; Zhou, J.; Verkh, L.; Smeraglia, J.; Mount, J.; Klamerus, K. J. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs, 2006, 17 (3), 353-358.
106. Watson, M. A.; Stewart, R. K.; Smith, G. B.; Massey, T. E.; Bell, D. A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis, 1998, 19 (2), 275-280.
107. van Erp, N. P.; Eechoute, K.; van der Veldt, A. A.; Haanen, J. B.; Reyners, A. K.; Mathijssen, R. H.; Boven, E.; van der Straaten, T.; Baak-Pablo, R. F.; Wessels, J. A.; Guchelaar, H. J.; Gelderblom, H. Pharmacogenetic pathway analysis for determination of sunitinibinduced toxicity. J. Clin. Oncol., 2009, 27 (26), 4406-4412.
108. Torisel (Temsirolimus) prescribing information. Wyeth Pharmaceuticals, Inc. http://www.pfizerpro.com/content/showlabeling.asp?id=490 (Accessed Oct 16, 2010)
109. Miller, D. S.; Fricker, G.; Drewe, J. p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J. Pharmacol. Exp. Ther., 1997, 282 (1), 440-444.
110. Wu, C.; Wangpaichitr, M.; Feun, L.; Kuo, M. T.; Robles, C.; Lampidis, T.; Savaraj, N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol. Cancer, 2005, 4 (1), 25.
111. Wangpaichitr, M.; Wu, C.; You, M.; Kuo, M. T.; Feun, L.; Lampidis, T.; Savaraj, N. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur. J. Pharmacol., 2008, 591 (1-3), 124-127.
112. Trisenox
113. Hipfner, D. R.; Deeley, R. G.; Cole, S. P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta, 1999, 1461 (2), 359-376.
114. Kala, S. V.; Neely, M. W.; Kala, G.; Prater, C. I.; Atwood, D. W.; Rice, J. S.; Lieberman, M. W. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem., 2000, 275 (43), 33404-33408.
115. Liu, J.; Chen, H.; Miller, D. S.; Saavedra, J. E.; Keefer, L. K.; Johnson, D. R.; Klaassen, C. D.; Waalkes, M. P. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol., 2001, 60 (2), 302-309.
116. Vernhet, L.; Courtois, A.; Allain, N.; Payen, L.; Anger, J. P.; Guillouzo, A.; Fardel, O. Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metalselected tumor cells. FEBS. Lett., 1999, 443 (3), 321-325.
117. Vernhet, L.; Allain, N.; Payen, L.; Anger, J. P.; Guillouzo, A.; Fardel, O. Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem. Pharmacol., 2001, 61 (11), 1387-1391.
118. Vernhet, L.; Seite, M. P.; Allain, N.; Guillouzo, A.; Fardel, O. Arsenic induces expression of the multidrug resistance-associated protein 2 (MRP2) gene in primary rat and human hepatocytes. J Pharmacol. Exp. Ther., 2001, 298 (1), 234-239.
119. Xie, Y.; Liu, J.; Liu, Y.; Klaassen, C. D.; Waalkes, M. P. Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice. Mol. Cell. Biochem., 2004, 255 (1-2), 11-18.
120. Takeshita, A.; Shinjo, K.; Naito, K.; Matsui, H.; Shigeno, K.; Nakamura, S.; Horii, T.; Maekawa, M.; Kitamura, K.; Naoe, T.; Ohnishi, K.; Ohno, R. P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells. Leukemia, 2003, 17 (3), 648-650.
121. Drobna, Z.; Walton, F. S.; Paul, D. S.; Xing, W.; Thomas, D. J.; Styblo, M. Metabolism of arsenic in human liver: the role of membrane transporters. Arch. Toxicol., 2010, 84 (1), 3-16.
122. Treanda (Bendamustine) prescribing information. Cephalon, Inc. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022249 s005lbl.pdf (Accessed Oct 18, 2010)
123. Apostolopoulos, C.; Castellano, L.; Stebbing, J.; Giamas, G. Bendamustine as a model for the activity of alkylating agents. Future Oncol., 2008, 4 (3), 323-332.
124. Ardekani, A. M.; Akhondi, M. M.; Sadeghi, M. R. Application of genomic and proteomic technologies to early detection of cancer. Arch Iran Med., 2008, 11 (4), 427-434.
125. Clolar (Clofarabine) Injection ofr intravenous use prescribing information. Genzyme. http://www.genzymeclinicalresearch.com/pdf/Clolar_pi.pdf (Accessed December 13,2010)
126. Bonate, P. L.; Arthaud, L.; Stuhler, J.; Yerino, P.; Press, R. J.; Rose, J. Q. The distribution, metabolism, and elimination of clofarabine in rats. Drug Metab. Dispos., 2005, 33 (6), 739-748.
127. Elwi, A. N.; Damaraju, V. L.; Baldwin, S. A.; Young, J. D.; Sawyer, M. B.; Cass, C. E. Renal nucleoside transporters: physiological and clinical implications. Biochem. Cell. Biol., 2006, 84 (6), 844-858.
128. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev., 2003, 55 (3), 425-461.
129. Pritchard, J. B.; Miller, D. S. Mechanisms mediating renal secretion of organic anions and cations. Physiol. Rev., 1993, 73 (4), 765-796.
130. Ajavon, A. D.; Bonate, P. L.; Taft, D. R. Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. Eur. J. Pharm. Sci., 2010, 40 (3), 209-216.
131. de, W. C.; Jansen, R.; Yamaguchi, H.; de, H. M.; van de Wetering, K.; Wijnholds, J.; Beijnen, J.; Borst, P. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol. Cancer Ther., 2008, 7 (9), 3092-3102.
132. Ixempra (ixabepilone) prescribing information. Bristol-Myers Squibb. http://packageinserts.bms.com/pi/pi_ixempra.pdf (Accessed Oct 18, 2010)
133. Lee, J. J.; Swain, S. M. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin. Oncol., 2005, 32 (6 Suppl 7), S22-S26.
134. McDaid, H. M.; Mani, S.; Shen, H. J.; Muggia, F.; Sonnichsen, D.; Horwitz, S. B. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin. Cancer Res., 2002, 8 (7), 2035-2043.
135. Wartmann, M.; Altmann, K. H. The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anticancer Agents, 2002, 2 (1), 123-148.
136. O'Reilly, T.; Wartmann, M.; Brueggen, J.; Allegrini, P. R.; Floersheimer, A.; Maira, M.; McSheehy, P. M. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother. Pharmacol., 2008, 62 (6), 1045-1054.
137. Arranon (nelarabine) prescribing information. GlaxoSmithKline. http://us.gsk.com/products/assets/us_arranon.pdf (Accessed Oct 18, 2010)
138. Lambe, C. U.; Averett, D. R.; Paff, M. T.; Reardon, J. E.; Wilson, J. G.; Krenitsky, T. A. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995, 55 (15), 3352-3356.
139. Cohen, M. H.; Johnson, J. R.; Massie, T.; Sridhara, R.; McGuinn, W. D., Jr.; Abraham, S.; Booth, B. P.; Goheer, M. A.; Morse, D.; Chen, X. H.; Chidambaram, N.; Kenna, L.; Gobburu, J. V.; Justice, R.; Pazdur, R. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin. Cancer Res., 2006, 12 (18), 5329-5335.
140. pemetrxed labeling
141. Uemura, T.; Oguri, T.; Ozasa, H.; Takakuwa, O.; Miyazaki, M.; Maeno, K.; Sato, S.; Ueda, R. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci., 2010. [Epub Ahead of Print]
142. Assaraf, Y. G. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat., 2006, 9 (4-5), 227-246.
143. Hooijberg, J. H.; de Vries, N. A.; Kaspers, G. J.; Pieters, R.; Jansen, G.; Peters, G. J. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother. Pharmacol., 2006, 58 (1), 1-12.
144. Praletrexate PI Folotyn (pralatrexate) prescribing information. Allos Therapeutics, Inc http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022468lbl.pdf (Accessed Oct 18, 2010)
145. Sirotnak, F. M.; Wendel, H. G.; Bornmann, W. G.; Tong, W. P.; Miller, V. A.; Scher, H. I.; Kris, M. G. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin. Cancer Res., 2000, 6 (9), 3705-3712.
146. Temodar (Temozolomide) prescriibing ifnroamtion. Merck and Co, Inc. http://www.spfiles.com/pitemodar.pdf (Accessed December 13, 2010)
147. Bleau, A. M.; Hambardzumyan, D.; Ozawa, T.; Fomchenko, E. I.; Huse, J. T.; Brennan, C. W.; Holland, E. C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell. Stem. Cell., 2009, 4 (3), 226-235.
148. Chua, C.; Zaiden, N.; Chong, K. H.; See, S. J.; Wong, M. C.; Ang, B. T.; Tang, C. Characterization of a side population of astrocytoma cells in response to temozolomide. J Neurosurg., 2008, 109 (5), 856-866.
149. Schaich, M.; Kestel, L.; Pfirrmann, M.; Robel, K.; Illmer, T.; Kramer, M.; Dill, C.; Ehninger, G.; Schackert, G.; Krex, D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol., 2009, 20 (1), 175-181.
150. Degarelix prescribing information. Ferring Pharmaceuticals Inc http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022201 lbl.pdf (Accessed Oct 18, 2010)
151. Australian Public Assessment Report for Degarelix. Australian Government 2010.
152. Femara (Letrozole) prescribing information. Novartis Pharmaceuticals Corporation. http://www.pharma.us.novartis.com/product/pi/pdf/Femara.pdf (Accessed December 13, 2010)
153. Bhattacharyya, R. S.; Krishnan, A. V.; Swami, S.; Feldman, D. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol. Cancer Ther., 2006, 5 (6), 1539-1549.
154. Femara (letrozole) prescribing information. 2010. Novartis Pharmaceuticals Corporation http://www.pharma.us.novartis.com/product/pi/pdf/Femara.pdf (Accessed Oct 18, 2010).
155. Evista (raloxifene hydrochloride) tablets. Eli Lilly and company http://pi.lilly.com/us/evista-pi.pdf (Accessed Oct 18, 2010).
156. Jeong, E. J.; Lin, H.; Hu, M. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol. Exp. Ther. 2004, 310 (1), 376-385.
157. Chang, J. H.; Kochansky, C. J.; Shou, M. The role of Pglycoprotein in the bioactivation of raloxifene. Drug Metab. Dispos. 2006, 34 (12), 2073-2078.
158. Bao, W.; Chen, B. A.; Gao, F.; Ding, J. H.; Xu, W. L.; Sheng, H. L.; Gao, C.; Sun, Y. Y.; Chen, J.; Wang, J.; Zhao, G.; Ma, Y. Effect of cyclosporine A, raloxifene and their combination on the reversion of multidrug resistance of K562/A02 line. Zhongguo Shi Yan. Xue. Ye. Xue. Za Zhi. 2006, 14 (5), 895-899.